Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2003

View Archived Issues

Alemtuzumab reported to increase clinical response and remission in refractory CLL

Emfilermin reported to improve implantation and pregnancy rates in women with RIF

Clinical trials assess the benefits and safety of metformin in women with PCOS

Buspirone in hot flashes in menopausal women

Safer antiarrhythmic agents newly developed at ARYx

Novel vitamin D analogues with utility in dermatological disorders designed at Galderma

New EGFR/HER2 kinase inhibitors under study at Wyeth

Ultrafine patent covers new agents with antimalarial and antitumor activity

BMS researchers present new compounds with factor VIIa/IMPDH-inhibitory activity

Filings announced for new rapid-acting insulin analogue

Erbitux submitted to E.U. and Swiss regulatory authorities

Roche licenses rights to market Avastin outside the U.S.

FDA decides against approval for Fortigel

ViroPharma advances towards the development of drug for smallpox

New indication cleared in Europe for Norditropin

Phase II trial of GTI-2040 in AML cleared by FDA

Enrollment imminent in phase III trial of Aryplase in MPS VI patients

Pravastatin improves cardiovascular risk in women with coronary heart disease

Good tolerability profile reported for IMC-1C11 in patients with metastatic colorectal cancer

GSK-3 inhibitors and their use claimed by Vertex

Promising clinical results for Mologen's dSLIM compounds in cancer patients

Antiviral efficacy of NM-283 shown in HCV-infected chimpanzees

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...